Two Sigma Investments LP Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Two Sigma Investments LP raised its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 5.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 664,040 shares of the company's stock after buying an additional 36,558 shares during the quarter. Two Sigma Investments LP owned about 0.17% of Moderna worth $27,611,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Assenagon Asset Management S.A. increased its holdings in shares of Moderna by 13.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 14,978 shares of the company's stock valued at $623,000 after purchasing an additional 1,819 shares during the period. Arkadios Wealth Advisors increased its holdings in shares of Moderna by 7.3% in the fourth quarter. Arkadios Wealth Advisors now owns 12,265 shares of the company's stock valued at $510,000 after purchasing an additional 836 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after purchasing an additional 389 shares during the period. Mirabaud & Cie SA increased its holdings in shares of Moderna by 3.0% in the fourth quarter. Mirabaud & Cie SA now owns 58,022 shares of the company's stock valued at $2,413,000 after purchasing an additional 1,694 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Moderna by 108.0% in the fourth quarter. SG Americas Securities LLC now owns 109,761 shares of the company's stock valued at $4,564,000 after purchasing an additional 56,982 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Down 1.7%

MRNA traded down $0.46 during trading on Friday, hitting $26.26. The company's stock had a trading volume of 8,237,982 shares, compared to its average volume of 8,009,025. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $164.73. The business's fifty day simple moving average is $27.08 and its 200 day simple moving average is $34.50. The firm has a market capitalization of $10.16 billion, a price-to-earnings ratio of -2.83 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period last year, the company earned ($3.07) earnings per share. Moderna's quarterly revenue was down 35.3% compared to the same quarter last year. As a group, equities research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research reports. Citigroup initiated coverage on Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective on the stock. UBS Group cut their price objective on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. William Blair reissued a "market perform" rating on shares of Moderna in a report on Thursday, April 17th. Barclays cut their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. Finally, Morgan Stanley dropped their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average price target of $53.58.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.